how many people are using glp-1 Products - Data Briefs - Number 537 68% of GLP-1 Users Say

Pembrolizumab and nivolumab are types of PD-1 inhibitors

Diabetologia 63 (2), 362373 (2020)

Interactions with immune checkpoint inhibitors and targeted therapies remain incompletely characterized, underscoring the need for pharmacovigilance and individualized risk assessment

Medication program persistence and engagement: January 2026 analysis of 30,239 Noom GLP-1 Rx Program members who started a GLP-1 Rx plan between December 2024 and February 2025, evaluating program persistence by engagement quartile

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials